{"organizations": [], "uuid": "6478b6d3790b222d87ac8f0278c964ea6f23d487", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aimmune-therapeutics-announces-201/brief-aimmune-therapeutics-announces-2018-outlook-including-upcoming-data-from-pivotal-phase-3-palisade-trial-of-ar101-for-peanut-allergy-idUSASB0C02P", "country": "US", "domain_rank": 408, "title": "BRIEF-Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.098, "site_type": "news", "published": "2018-01-08T21:15:00.000+02:00", "replies_count": 0, "uuid": "6478b6d3790b222d87ac8f0278c964ea6f23d487"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aimmune-therapeutics-announces-201/brief-aimmune-therapeutics-announces-2018-outlook-including-upcoming-data-from-pivotal-phase-3-palisade-trial-of-ar101-for-peanut-allergy-idUSASB0C02P", "ord_in_thread": 0, "title": "BRIEF-Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy", "locations": [], "entities": {"persons": [], "locations": [{"name": "palisade", "sentiment": "none"}, {"name": "palisade", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "aimmune therapeutics inc", "sentiment": "neutral"}, {"name": "palisade", "sentiment": "none"}, {"name": "artemis", "sentiment": "none"}, {"name": "regeneron", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Aimmune Therapeutics Inc:\n* AIMMUNE THERAPEUTICS - PALISADE COMPLETED IN 2017; TOPLINE RESULTS ANTICIPATED IN FEBRUARY\n* AIMMUNE THERAPEUTICS INC - AR101 BLA SUBMISSION EXPECTED AT END OF 2018\n* AIMMUNE THERAPEUTICS ANNOUNCES 2018 OUTLOOK, INCLUDING UPCOMING DATA FROM PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 FOR PEANUT ALLERGY\n* AIMMUNE THERAPEUTICS - ARTEMIS TRIAL IS ON TRACK TO COMPLETE ENROLLMENT IN Q1 OF 2018, EXPECTS DATA FROM ARTEMIS IN EARLY 2019\n* AIMMUNE THERAPEUTICS INC - ENDED 2017 WITH ABOUT $182 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017\n* AIMMUNE THERAPEUTICS INC- 2018 PLANS INCLUDE INITIATION OF ARC005 CLINICAL TRIAL OF AR101 FOR PEANUT ALLERGY IN YOUNG CHILDREN AGES 6-48 MONTHS\n* AIMMUNE THERAPEUTICS - 2018 PLANS ALSO INCLUDE INITIATION, WITH REGENERON AND SANOFI, OF PHASE 2 CLINICAL TRIAL OF AR101 AND ADJUNCTIVE DUPILUMAB\n* AIMMUNE - ALSO EXPECTS TO FILE IND APPLICATION FOR EGG ALLERGY PROGRAM IN 2018, CONTINUE WORK TOWARD FILING IND FOR WALNUT ALLERGY IN 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:15:00.000+02:00", "crawled": "2018-01-09T17:16:24.000+02:00", "highlightTitle": ""}